Laureano Simón, CEO of Oncomatryx, explains on “La Ventana” how this new treatment could reverse metastasis. A Spanish drug offers new hope to patients with metastatic cancer There is still no cure for cancer, but investment in research and technology is making it possible for many cancer patients to enjoy a better quality of life … Read more
BILBAO, Spain— Oncomatryx Biopharma, a biotechnology company pioneering next-generation Antibody-Drug Conjugates (ADCs) for oncology, has been awarded funding from the European Innovation Council (EIC) Accelerator under the EU’s Horizon Europe 2021-2027 Research and Innovation Program. As part of this highly competitive program, Oncomatryx will receive €2.5 million in grant funding, along with a €10 million equity … Read more
ONCOMATRYX, a biopharmaceutical company developing novel ADCs against the tumor microenvironment, has successfully raised €25 million, to fund Phase Ib-II clinical trials of OMTX705, a first-in-class ADC targeting FAP. The funding round was led by the company’s existing investors and included a €10 million strategic investment from Centro para el Desarrollo Tecnologico e Innovacion (CDTI). … Read more
